Core Viewpoint - Sera Prognostics, Inc. has announced a proposed underwritten public offering of its Class A common stock to enhance its commercial infrastructure and capabilities, particularly in the U.S. and for potential expansion into the European Union [1][3]. Group 1: Offering Details - The company is offering Class A common stock and pre-funded warrants to purchase shares of Class A common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of the total shares offered [1]. - Jefferies, TD Cowen, and William Blair are acting as joint book-running managers, while RBC Capital Markets is serving as a bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to expand commercial infrastructure in the U.S., accelerate preparations for EU expansion, fund studies to increase adoption of the PreTRM test, and for general corporate purposes [3]. Group 3: Company Overview - Sera Prognostics is focused on improving maternal and neonatal health through innovative pregnancy biomarker information, with a mission to provide early pregnancy information to reduce healthcare delivery costs [6]. - The company has developed the PreTRM® Test, which assesses the risk of spontaneous premature delivery, allowing for proactive interventions [6].

Core Insights - Sera Prognostics Inc. is hosting a virtual R&D day on January 31, 2025, to present results from its pivotal PRIME study, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information [1][2] Company Overview - Sera Prognostics is dedicated to enhancing the lives of women and babies by providing early pregnancy information aimed at improving health outcomes and reducing healthcare costs [4] - The company has a robust pipeline of diagnostic tests, including the PreTRM® Test, which predicts the risk of spontaneous preterm birth, allowing for proactive interventions [4][6] Study and Test Details - The PRIME study aims to assess the effectiveness of clinical interventions in improving neonatal outcomes related to preterm birth [2] - The PreTRM® Test is the only validated blood-based biomarker test that provides individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, enabling informed clinical decisions [6] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with significant long-term health implications and estimated annual healthcare costs of approximately $25 billion in the U.S. [5]

Core Insights - Sera Prognostics, Inc. announced that the results of the PRIME study will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting on January 31, 2025 [1][2] - The PRIME study evaluated the effectiveness of the PreTRM test in identifying pregnant women at higher risk of preterm delivery and its impact on neonatal outcomes [2][4] - The PreTRM test is a blood-based biomarker test that provides individualized risk predictions for spontaneous preterm birth [6] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative diagnostic tests aimed at early prediction of preterm birth risk [4] - The company is headquartered in Salt Lake City, Utah, and focuses on precision pregnancy care to reduce healthcare delivery costs [4] Study Details - The PRIME study, which stands for Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes, achieved at least one primary endpoint at the required statistical significance level during its interim analysis [2] - The study's enrollment was halted in December 2023, and the company has since concentrated on data gathering and analysis for the complete cohort [2] Industry Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [5] - The March of Dimes Report Card indicates that over 10% of infants in the U.S. are born prematurely, with significant long-term medical complications associated with prematurity [5] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5]

Core Viewpoint - Sera Prognostics Inc. is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, and will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 [1] Company Overview - Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company aims to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [4] - Over the last five years, more than one in ten infants in the United States has been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [4] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test measures and analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify women at increased risk during weeks 18 through 20 of pregnancy [5] - The PreTRM® Test enables more informed, personalized clinical decisions based on each woman's individual risk [5]

SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and d ...

Sera Prognostics Inc (NASDAQ:SERA) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes. I would now li ...

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%.Over the last four quarters, the company has n ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organiza ...

Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Recent Highlights: Salt Lake City – November 6, 2024 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. • Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Impro ...

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024.Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locke ...